Motor function performance in individuals with RYR1-related myopathies

被引:6
|
作者
Witherspoon, Jessica W. [1 ]
Vuillerot, Carole [2 ,3 ,4 ]
Vasavada, Ruhi P. [5 ]
Waite, Melissa R. [5 ]
Shelton, Monique [1 ]
Chrismer, Irene C. [1 ]
Jain, Minal S. [5 ]
Meilleur, Katherine G. [1 ]
机构
[1] NINR, NIH, Bethesda, MD 20892 USA
[2] Hosp Civils Lyon, Hop Femme Mere Enfant, Escale, Serv Med Phys & Readaptat Pediat, F-69500 Bron, France
[3] Univ Lyon, F-69000 Lyon, France
[4] Univ Lyon 1, F-69100 Villeurbanne, France
[5] NIH, Rehabil Med, Bldg 10, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
disease progression; GFT; MFM; motor function; RYR1; DUCHENNE MUSCULAR-DYSTROPHY; CONGENITAL MYOPATHIES; RYR1;
D O I
10.1002/mus.26491
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction The objective of this study was to obtain a 6-month natural history of motor function performance in individuals with RYR1- related myopathy (RYR1-RM) by using the Motor Function Measure-32 (MFM-32) and graded functional tests (GFT) while facilitating preparation for interventional trials. Methods In total, 34 participants completed the MFM-32 and GFTs at baseline and 6-month visits. Results Motor deficits according to MFM-32 were primarily observed in the standing and transfers domain (D1; mean 71%). Among the GFTs, participants required the most time to ascend/descend stairs (>7.5 s). Functional movement, determined by GFT grades, was strongly correlated with MFM-32 (D1; r >= 0.770, P < 0.001). Motor Function Measure-32 and GFT scores did not reflect any change in performance between baseline and 6-month visits. Discussion The MFM-32 and GFTs detected motor impairment in RYR1-RM, which remained stable over 6 months. Thus, these measures may be suitable for assessing change in motor function in response to therapeutic intervention. Muscle Nerve 60: 80-87, 2019
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [41] Correction to: Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcysteine therapy
    Carlos Capella-Peris
    Mary M. Cosgrove
    Irene C. Chrismer
    Magalie Emile-Backer
    M. Sonia Razaqyar
    Jeffrey S. Elliott
    Anna Kuo
    Paul G. Wakim
    Katherine G. Meilleur
    Quality of Life Research, 2020, 29 : 2183 - 2183
  • [42] Local muscle strength, oxygen extraction capacity, and exercise capacity in adults with RYR1-related myopathies: Exploratory study
    Witherspoon, J.
    Drinkard, B.
    Waite, M.
    Arveson, I.
    Stockman, M.
    Jain, M.
    Meilleur, K.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S135 - S135
  • [43] Using Cluster Analysis to Overcome the Limits of Traditional Phenotype-Genotype Correlations: The Example of RYR1-Related Myopathies
    Dosi, Claudia
    Rubegni, Anna
    Baldacci, Jacopo
    Galatolo, Daniele
    Doccini, Stefano
    Astrea, Guja
    Berardinelli, Angela
    Bruno, Claudio
    Bruno, Giorgia
    Comi, Giacomo Pietro
    Donati, Maria Alice
    Dotti, Maria Teresa
    Filosto, Massimiliano
    Fiorillo, Chiara
    Giannini, Fabio
    Gigli, Gian Luigi
    Grandis, Marina
    Lopergolo, Diego
    Magri, Francesca
    Maioli, Maria Antonietta
    Malandrini, Alessandro
    Massa, Roberto
    Mata, Sabrina
    Melani, Federico
    Messina, Sonia
    Mignarri, Andrea
    Moggio, Maurizio
    Pennisi, Elena Maria
    Pegoraro, Elena
    Ricci, Giulia
    Sacchini, Michele
    Schenone, Angelo
    Sampaolo, Simone
    Sciacco, Monica
    Siciliano, Gabriele
    Tasca, Giorgio
    Tonin, Paola
    Tupler, Rossella
    Valente, Mariarosaria
    Volpi, Nila
    Cassandrini, Denise
    Santorelli, Filippo Maria
    GENES, 2023, 14 (02)
  • [44] Genetic and clinical heterogeneity of RYR1-related myopathies in a cohort of 60 Dutch families with identification of 40 novel mutations
    Voermans, N. C.
    Jungbluth, H.
    Raaphorst, J.
    Snoeck, M.
    Straathof, C.
    Schelhaas, H. J.
    Sie, L.
    de Coo, R.
    van de Pol, W.
    de Visser, M.
    Scheffer, H.
    Kamsteeg, E. J.
    van Engelen, B. G. M.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 841 - 841
  • [45] Parental mosaicism in RYR1-related Central Core Disease
    Marks, S.
    van Ruitenbeek, E.
    Fallon, P.
    Johns, P.
    Phadke, R.
    Mein, R.
    Mohammed, S.
    Jungbluth, H.
    NEUROMUSCULAR DISORDERS, 2018, 28 (05) : 422 - 426
  • [46] Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
    Siciliani Scalco, R.
    Voermans, N. C.
    Jungbluth, H.
    Quinlivan, R.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S38 - S38
  • [47] Mouse model of severe recessive RYR1-related myopathy
    Brennan, Stephanie
    Garcia-Castaneda, Maricela
    Michelucci, Antonio
    Sabha, Nesrin
    Malik, Sundeep
    Groom, Linda
    LaPierre, Lan Wei
    Dowling, James J.
    Dirksen, Robert T.
    HUMAN MOLECULAR GENETICS, 2019, 28 (18) : 3024 - 3036
  • [48] Phase 1 open-label trial of Rycal S48168 (ARM210) for RYR1-related myopathies
    Todd, J.
    Lawal, T.
    Chrismer, I.
    Kokkinis, A.
    Grunseich, C.
    Jain, M.
    Waite, M.
    Barnes, M.
    Biancavilla, V.
    Pocock, S.
    Brooks, K.
    Reikof, W.
    Emile-Backer, M.
    Marks, A.
    Webb, Y.
    Marcantonio, E.
    Foley, A.
    Meilleur, K.
    Bonnemann, C.
    Mohassel, P.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S46 - S46
  • [49] Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
    Scalco, R.
    Voermans, N.
    Jungbluth, H.
    Quinlivan, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 689 - 689
  • [50] Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
    Scalco, R. S.
    Voermans, N. C.
    Piercy, R. J.
    Jungbluth, H.
    Quinlivan, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (08) : E56 - E57